SYK and leukemia: Fostamatinib (R788) is one of the latest reported inhibitors of both SYK and PI3K leukemia proteins; its action mechanism relates to the blocking of antigen-dependent B-cell-receptor signaling [66,67]; thus, based on its already known antileukemial activy, it was used as the control ligand in the docking study.